The size of the Asia Pacific Gastroparesis Drugs market was around USD 1.10 Billion in 2021. It is expected to grow at a CAGR of 5.5% to reach USD 1.43 billion by 2026. It captures 20% of the global market.
Y-O-Y rise in the incidence rate of diabetes population, an increase in the number of surgical procedures, and an increase in the geriatric population in the APAC region are primarily fueling the growth rate of the APAC gastroparesis drugs market. In addition, continuous adoption of gastroparesis treatments is another factor accelerating the market's growth. Furthermore, Prokinetics drug is expected to aid in developing the gastroparesis drug market by increasing the frequency of contractions and improving gastrointestinal motility.
Furthermore, the rising prevalence of diabetic Mellitus in the Asia Pacific is driving up demand for diagnostic and treatment, and diabetes is a prominent cause of gastroparesis, propelling the gastroparesis medicine market forward. One of the other key factors is that gastroparesis is on the rise, as this is a highly prevalent type of gastroparesis with no known etiology and symptoms of vomiting, nausea, upper abdominal pain. Dietary changes, antiemetic medicine therapy, prokinetics medication, and symptoms modulators can all help to alleviate these symptoms.
It impairs regular digestion, induces vomiting, and causes blood sugar and nutrition issues, and gastroparesis is treated with various pharmaceuticals and treatments, including reglan, erythromycin, antiemetics, and others. This boosts demand for these treatments and, to some extent, the overall market.
However, side effects from gastroparesis medications, a lengthy regulatory process for therapeutic approval, and difficulties in diagnosing gastroparesis may impede the market. The lack of scientific data on the improvement delivered by prescription medications and the end of clinical trials further impose a negative impact on the gastroparesis drugs market in the APAC region.
This research report on the Asia Pacific Gastroparesis Drugs market has been segmented and sub-segmented into the following categories.
By Drug Class:
By Disease Class:
By End User:
By Country:
Geographically, Asia Pacific is the fastest-growing market and is anticipated to remain in the forecast period. Emerging economies of India and China are spearheading this growth spurt. According to the Centers for Disease Control and Prevention, over 84 million Americans had prediabetes in 2019, resulting in a high prevalence of gastroparesis and regionally driving the gastroparesis medicine market. Additionally, rising healthcare expenditures, an increase in the number of hospitals, and the presence of well-established healthcare infrastructure are also contributing to the overall regional market's growth.
Many market participants find the Asia-Pacific region to be a lucrative prospect, as nations such as India have a high prevalence rate of diabetes, which leads to gastroparesis conditions and will contribute to the gastroparesis medicine market. Furthermore, during the forecast period, a surge in demand for user-friendly medicine development, increased healthcare infrastructure, and creative marketing initiatives by leading vendors in growing nations such as India, China, and Japan are projected to present profitable prospects for market expansion.
KEY MARKET PLAYERS:
Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma is a few of the prominent companies in the gastroparesis drugs market in the APAC region.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 Prokinetic Agents
5.1.3 Antiemetic Agents
5.1.4 Botulinum Toxin Injections
5.1.5 Y-o-Y Growth Analysis, By Drug Class
5.1.6 Market Attractiveness Analysis, By Drug Class
5.1.7 Market Share Analysis, By Drug Class
5.2 Disease Type
5.2.1 Introduction
5.2.2 Diabetic Gastroparesis
5.2.3 Idiopathic Gastroparesis
5.2.4 Post-surgical Gastroparesis
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By Disease Type
5.2.7 Market Attractiveness Analysis, By Disease Type
5.2.8 Market Share Analysis, By Disease Type
5.3 End User
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Pharmacies
5.3.4 Clinics
5.3.5 E-commerce
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Class
6.1.3.3 By Disease Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Class
6.1.4.3 By Disease Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Class
6.1.5.3 By Disease Type
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allergan, Plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)
8.3 AstraZeneca Plc.
8.4 Cadila Pharmaceuticals Ltd.
8.5 ETX Pharma, Inc
8.6 Evoke Pharma
8.7 GlaxoSmithKline Plc.
8.8 Neurogastrx, Inc.
8.9 Valeant Pharmaceuticals International, Inc.
8.10 Theravance Biopharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
